Atyr Pharma Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>AP</div>
LIFE -- USA Stock  

USD 4.50  0.18  4.17%

Atyr Pharma Average Equity is projected to increase significantly based on the last few years of reporting. The past year's Average Equity was at 30.94 Million. The current year Enterprise Value is expected to grow to about 11.7 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (21.6 M). As many baby boomers are still indifferent towards healthcare space, it makes sense to digest Atyr Pharma. We will evaluate if Atyr Pharma shares are reasonably priced going into April. In this post, I will also go over some essential variables affecting Atyr Pharma's products, and show how it may impact Atyr Pharma outlook for active traders this year.
Published over two weeks ago
View all stories for Atyr Pharma | View All Stories
Is Atyr Pharma overvalued?
On a scale of 0 to 100, Atyr Pharma holds a performance score of 4. The firm shows a Beta (market volatility) of 0.9713, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Atyr Pharma's beta means in this case. Atyr Pharma returns are very sensitive to returns on the market. As the market goes up or down, Atyr Pharma is expected to follow. Although it is vital to follow Atyr Pharma historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Atyr Pharma, which you can use to evaluate the performance of the firm. Please makes use of Atyr Pharma potential upside, accumulation distribution, price action indicator, as well as the relationship between the expected short fall and day median price to make a quick decision on whether Atyr Pharma price patterns will revert.

How important is Atyr Pharma's Liquidity

Atyr Pharma financial leverage refers to using borrowed capital as a funding source to finance Atyr Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Atyr Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Atyr Pharma's total debt and its cash.

How Atyr Pharma utilizes its cash?

To perform a cash flow analysis of Atyr Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Atyr Pharma is receiving and how much cash it distributes out in a given period. The Atyr Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Atyr Pharma Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (15.3 Million)

What is driving Atyr Pharma Investor Appetite?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Atyr Pharma has an asset utilization ratio of 6.59 percent. This indicates that the company is making $0.0659 for each dollar of assets. An increasing asset utilization means that Atyr Pharma is more efficient with each dollar of assets it utilizes for everyday operations.

A growth case for Atyr Pharma

Treynor ratio is down to 0.65. It may indicate a possible volatility dip. Atyr Pharma is displaying above-average volatility over the selected time horizon. Investors should scrutinize Atyr Pharma independently to ensure intended market timing strategies are aligned with expectations about Atyr Pharma volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Atyr Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Atyr Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Atyr Pharma

Although some companies under the biotechnology industry are still a bit expensive, Atyr Pharma may offer a potential longer-term growth to shareholders. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Atyr Pharma as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Atyr Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Atyr Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com